Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	14.75B
Revenue (ttm)	31.76M
Net Income (ttm)	-102.73M
Shares Out	126.60M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,239
Average Volume	170,140
Open	115.00
Previous Close	115.50
Day's Range	115.00 - 116.50
52-Week Range	96.00 - 210.00
Beta	0.63
RSI	54.07
Earnings Date	Apr 17, 2025

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2023, Gongwin Biopharm Holdings's revenue was 18.92 million, an increase of 1554.86% compared to the previous year's 1.14 million. Losses were -101.18 million, -65.37% less than in 2022.